Eisai Co. Ltd. (ESAIY PINK) stock market data APIs
$6.9967
0.04(0.6%)
as of February 9, 2026
Try our APIs with
free plan!
Eisai Co. Ltd. Financial Data Overview
Price chart is built with
Anychart
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals. It also offers prescription medicines. In addition, the company focuses on neurology and oncology and therapeutic areas. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
Prev. Close
6.9967
Open
7.0335
High
7.0744
Low
6.9185
52 wk Range
5.8688-9.1094
Market Cap
7 911 M
P/E Ratio
24.75
Shares Outstanding
1 128 M
Revenue
808 186 M
Dividends (Yield)
0.0382
Beta
-0.275
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Eisai Co. Ltd. data using free add-ons & libraries
Get Eisai Co. Ltd. Fundamental Data
Eisai Co. Ltd. Fundamental data includes:
- Net Revenue: 808 186 M
- EBITDA: 89 009 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-02-04
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Eisai Co. Ltd. News
New
Eisai GAAP EPS of ¥148.31, revenue of ¥619.95B; reaffirms FY outlook
* Eisai press release [https://www.eisai.com/ir/library/settlement/pdf/eFY2025Q3_51.pdf] (ESALF [https://seekingalpha.com/symbol/ESALF]): for the Nine-Month Period Ended December 31, 2025 reported ...
BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China
STOCKHOLM, Feb. 9, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ: BIOA B (Stockholm: BIOA B) partner Eisai announced today that the Biologics License Application (BLA) for the treatment of early...
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China
Biogen Inc. TOKYO and CAMBRIDGE, Mass., Feb. 08, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: C...
Biogen Hits 52-Week High, Alzheimer's Drug Sales Jump
Biogen Inc.(NASDAQ:BIIB) on Friday reported better-than-expected fourth-quarter earnings, with adjusted EPS of $1.99, beating the consensus of $1.59. The Alzheimer's drug maker reported revenues of $...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
